Exploring end-stage liver disease in China
Real World Study of End-stage Liver Disease in China
This study looks at how end-stage liver disease is currently being diagnosed and treated in China to see if better methods can help patients with liver cirrhosis and its complications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Huashan Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT04037995 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the current situation of end-stage liver disease in China, focusing on the optimization of diagnosis and treatment. It will analyze various forms of liver cirrhosis, including those caused by hepatitis and alcohol, and their associated complications such as portal hypertension and hepatic encephalopathy. The study is single-center and prospective, gathering real-world data to standardize treatment approaches for liver cirrhosis and its complications. By understanding the epidemiological landscape, the study seeks to inform better empirical treatment plans for patients.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with acute decompensation of cirrhosis, chronic liver failure, or hepatocellular carcinoma (stage III-IV) who can provide informed consent.
Not a fit: Patients with serious psychiatric conditions, other malignant tumors, or significant organ diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment protocols for patients suffering from end-stage liver disease.
How similar studies have performed: While there is ongoing research in this area, this specific observational approach focusing on the Chinese population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Informed consent of patients. 2. Diagnosis of any of the following diseases: acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure and hepatocellular carcinoma (stage III-IV) Exclusion Criteria: 1. HIV antibody positive and AIDS patients 2. Serious psychiatric history, especially depression. Severe mental illness is defined as major depression or psychosis, suicide attempts, hospitalization due to mental illness or a period of disability due to mental illness. 3. Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs. 4. Patients with other malignant tumors (excluding those cured). 5. Pregnant, lactating women or women of childbearing age who are ready to conceive.
Where this trial is running
Shanghai, Shanghai Municipality
- HuaShan Hospital — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Jingwen Ai, Doctor
- Email: JINGWENAI1990@126.COM
- Phone: 13764990804
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.